DELIVER NEW
TREATMENTS

Tackling cancer by leveraging multiple modalities

Our oncology programs encompass multiple modalities, including a PD-1 x VEGF bispecific antibody that we see as a foundational backbone, as well as antibody-drug conjugates (ADCs) that could be utilized alone and in combination with our immunotherapy candidate. We’re working smartly and efficiently by leveraging established targets and validated biology, with the goal of advancing rapidly towards multiple solid tumor indications.

Delivering a pipeline of potentially best-in-class therapies for the treatment of solid tumors
Program
Combination
Indications
Phase/Stage
Development Region
CR-001
PD-1 x VEGF bsAb
Same cooperative MoA as ivonescimab
Monotherapy &
SOC chemo combo
NSCLC & other
solid tumors
Phase/Stage
ASCEND Phase 1/2
Global (Ex-China)
Greater China
sac-TMT
TROP2 Topo1i ADC
NSCLC
Phase/Stage
Phase 2
Greater China
sac-TMT
TROP2 Topo1i ADC
2L nsq NSCLC*
Phase/Stage
Phase 2
Greater China
sac-TMT
TROP2 Topo1i ADC
Solid tumors
Phase/Stage
Phase 2
Greater China
CR-002
PD-L1 Topo1i ADC
Monotherapy
NSCLC, HNSCC,
other solid tumors
Phase/Stage
APOLLO Phase 1/2
Global (Ex-China)
CR-003 (SKB105)
ITGB6 Topo1i ADC
Monotherapy
Solid tumors
Phase/Stage
Phase 1/2
Global (Ex-China)
Greater China
CR-004
Undisclosed ADC
Monotherapy
Solid tumors
Phase/Stage
Preclinical
NSCLC: Non-small cell lung cancer. HNSCC: Head and neck squamous cell carcinoma. MoA: Mechanism of action. ADC: Antibody-drug conjugate. Topo1i: Topoisomerase 1 inhibitor; Ex-China = Ex-Greater China. Greater China includes mainland China, Hong Kong, Macau and Taiwan. CR-001 also known as SKB118.

*Participants with locally advanced or metastatic non-squamous NSCLC harboring EGFR-sensitizing mutations who have failed EGFR-TKI therapy.
logo Crescent logo biotech

CR-001

A cooperative tetravalent
bispecific antibody with the same
MOA as ivonescimab

Our lead program, CR-001, is a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors. We are focused on potential first-in-class and fast follower opportunities with a rapid path to market and high probability of success based on clinical validation from approved VEGF and PD-(L)1 therapies.

CR 001 was intentionally designed to exhibit the cooperative pharmacology of ivonescimab, another tetravalent PD-1 x VEGF bispecific antibody that has demonstrated superior efficacy vs market-leading pembrolizumab in a large, third-party Phase 3 clinical trial.1 CR 001 s PD-1 checkpoint inhibition is aimed at restoring T cells ability to recognize and destroy tumor cells. Its structure may also promote localization of anti-VEGF activity into the tumor microenvironment, potentially helping to concentrate therapeutic exposure within the tumor and limit systemic exposure..

CR 001 is being evaluated in ASCEND, a global Phase 1/2 trial in patients with advanced solid tumors, and in combination regimens designed to leverage its anti-VEGF activity to normalize tumor vasculature and potentially improve the delivery and effectiveness of therapies, such as antibody-drug conjugates (ADCs).

Crescent has granted its partner, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., exclusive rights to research, develop, and commercialize CR 001 (also known as SKB118) in Greater China.

In China, Kelun-Biotech is evaluating CR 001 in combination with sacituzumab tirumotecan (sac-TMT), its TROP2-directed ADC, in multiple studies. Combination studies with additional ADCs including CR 002 and CR 003 are also planned.

Novel, cooperative PD-1 x VEGF MOA may drive enhanced anti-tumor activity while maintaining tolerability
Tumor targeting
  • Dual blockade of PD-1 and VEGF through a novel tetravalent bispecific format with cooperative binding effects has led to unprecedented clinical results in third-party trials
  • PD-1 arm concentrates VEGF inhibition in the TME, potentially sparing healthy tissue and reducing AEs
Cooperativity
  • The cooperative binding with an agent such as CR-001 may block PD-1/PD-L1 interactions and inhibit VEGF
  • VEGF binding to an agent like CR-001 may increase affinity to PD-1 and vice versa, enhancing both T cell activation and VEGF signaling blockade
  • PD-1 binding strength (affinity) is increased in the presence of VEGF

Reference: 1. Xiong A et al. Lancet. 2025;405(10481):839–849.

Potentially best-in-class ADCs with topoisomerase inhibitor payloads

CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as monotherapy and in combination with CR-001 with significant potential across solid tumor indications.

CR-002

topoisomerase inhibitor
ADC targeting PD-L1

CR-002 is a topoisomerase inhibitor ADC directed to PD-L1, a validated target known to have high expression in multiple solid tumors. CR-002 incorporates a PD-L1 antibody selected for high internalization to facilitate payload release in target cells and a linker designed for intracellular cleavage and high stability in circulation. The U.S. Food and Drug Administration (FDA) has cleared Crescent’s Investigational New Drug (IND) application for CR-002, and the company plans to initiate APOLLO, a global Phase 1/2 clinical trial in patients with advanced solid tumors in the fourth quarter of 2026.

CR-003 (SKB105)

topoisomerase inhibitor ADC
targeting integrin beta-6

CR-003 (also known as SKB105) is a differentiated ADC targeting integrin beta-6 (ITGB6) with a topoisomerase 1 inhibitor payload. ITGB6 is overexpressed in many solid 
tumors, but shows minimal to no expression in most normal tissues, thereby potentially reducing the risk of systemic 
toxicity and off-target effects. CR-003 consists of an anti-ITGB6 fully human IgG1 monoclonal antibody conjugated via a stable, clinically validated cleavable linker. The molecule incorporates proprietary Kthiol irreversible conjugation technology, designed to enhance stability and tumor-specific payload delivery while reducing adverse effects. CR-003 demonstrated a favorable efficacy, safety, and pharmacokinetic (PK) profile in preclinical models.

Under its strategic collaboration, Kelun-Biotech granted Crescent exclusive rights to research, develop, and commercialize CR-003 (SKB105) in the United States, Europe and all markets outside of Greater China.

A Phase 1/2 clinical trial of CR-003 in patients with advanced solid tumors in China is ongoing.

Pipeline Expansion Opportunities

Crescent also plans to continue to pursue opportunities to advance its strategy in immuno-oncology and best-in-class ADC combinations through internal efforts and with leading partners, including Kelun-Biotech and Paragon Therapeutics.

Presentations & Publications

October 23, 2026
European Society for Medical Oncology (ESMO) Congress 2026
ASCEND: A phase 1/2, dose-escalation, optimization, and dose-expansion study to evaluate the safety and antitumor activity of CR-001 in adults with locally advanced or metastatic solid tumors
May 30, 2026
2026 American Society of Clinical Oncology (ASCO) Annual Meeting
ASCEND: A phase 1/2, dose-escalation, optimization, and dose-expansion study to evaluate the safety and antitumor activity of CR-001 in adults with locally advanced or metastatic solid tumors
November 7, 2025
Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
Preclinical development of CR-001, a novel tetravalent PD-1 x VEGF bispecific antibody with cooperative pharmacology and potent anti-tumor activity